Skip to main content
CMMB logo

Chemomab Therapeutics Ltd. (CMMB) Stock Price & Analysis

Chemomab Therapeutics Ltd. (CMMB) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $1.14 (-26.45%), as of the Nov 19, 2026 trading session; market cap $9.18M.

Educational signal · not a buy or sell recommendation · How to read this

$1.14 −$0.41 (-26.45%) Market Cap $9.18M

Chemomab Therapeutics Ltd. · CMMB · NASDAQ

Chemomab Therapeutics Ltd. is a clinical-stage biotech company focused on developing therapeutics for inflammation and fibrosis.

Price as of Nov 19, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Chemomab Therapeutics (CMMB)

Weak
Business Quality Thin (30)
Financial Safety Okay (43)
Valuation Bubble (7)
Growth Durability Flat (56)
Momentum Quiet (53)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality and an expensive valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Flat; Momentum: Quiet.

Free cash flow yield is the main valuation drag relative to sector peers.

  • EPS beat 1 of the last 8 reports
  • Altman Z -12.85 · Piotroski F 0
  • ROE -70.8% · ROA -74.3% · current ratio 6.41 · earnings yield -58.6% · free-cash-flow yield -95.6%

Holding back: weak fundamentals, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CMMB (52 recorded, newest six shown)
RecordedScoreBand
30Weak
30Weak
30Weak
30Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.14
Change on the day-26.45%
52-week range$0.92 – $2.99
Market capitalisation$9.18M—
Shares traded on the day90.8K

Price & events

Other perspectives

Council score for Chemomab Therapeutics (CMMB): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Negative
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Chemomab Therapeutics (CMMB), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Chemomab Therapeutics Ltd. (CMMB) is listed on NASDAQ. It employs 12 people and is led by Adi Mor George. The market values it at $9.18M.

2 · Latest results

What do the latest results show for Chemomab Therapeutics (CMMB)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Chemomab Therapeutics (CMMB)?

Short answer · as of

What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -12.85 · Piotroski F 0. Trailing ratios: ROE -70.8% · ROA -74.3% · current ratio 6.41 · earnings yield -58.6% · free-cash-flow yield -95.6%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -12.85 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-70.8%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Chemomab Therapeutics (CMMB)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $24.40M · EPS -0.02 · 2 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for CMMB.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Chemomab Therapeutics compare with its peers?

Short answer

Chemomab Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
Chemomab Therapeutics (CMMB) — this page$1.14$9.18M32

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$24.40M
EPS estimate
$-0.02

Measured against a quoted price of $1.14 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CMMB in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CMMB in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Chemomab Therapeutics (CMMB)

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for CMMB?

CMMB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is CMMB a good stock to buy?

Stock Expert AI does not rate CMMB buy, sell or hold. Chemomab Therapeutics Ltd. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CMMB stock price today?

The last price recorded for Chemomab Therapeutics Ltd. (CMMB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for CMMB?

Chemomab Therapeutics Ltd. (CMMB) holds a MoonshotScore in the low range. Analysts target $5.00 (+339%). Not financial advice.

How frequently does CMMB data refresh on this page?

CMMB's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CMMB's recent stock price performance?

Chemomab Therapeutics Ltd. (CMMB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CMMB overvalued or undervalued right now?

Chemomab Therapeutics Ltd. (CMMB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CMMB before investing?

Before investing in Chemomab Therapeutics Ltd. (CMMB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CMMB to a portfolio?

No dossier-level strength is on record for Chemomab Therapeutics Ltd. (CMMB) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 4 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.